Mirum Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Great. Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we are delighted to be continuing the conference today with Mirum.
Format is a little different this year. We don't have to all shuffle over to another room for Q&A. The Q&A is going to happen right here after the presentation concludes. (Operator Instructions)
So with that out of the way, let me turn it over to Mirum's CEO, Chris Peetz.
Thanks, Jess, and thanks, everyone, for the interest in Mirum. Excited to walk through the story here today.
I'm going to just make some kind of overview comments, dive a little bit deeper into our commercial program in Alagille syndrome, talk about some of the pipeline across pediatric and adult cholestasis and then kind of wrap up the story and why we're so excited about 2023.
I'd be making forward-looking statements. So I'll refer you
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
